

# Susana Rosello Keranen

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/9055590/susana-rosello-keranen-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

75  
papers

2,019  
citations

25  
h-index

43  
g-index

87  
ext. papers

2,526  
ext. citations

5.4  
avg, IF

4.48  
L-index

#	Paper	IF	Citations
75	Current questions for the treatment of advanced gastric cancer. <i>Cancer Treatment Reviews</i> , <b>2013</b> , 39, 60-7	14.4	133
74	Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. <i>Breast Cancer Research and Treatment</i> , <b>2009</b> , 114, 479-84	4.4	125
73	Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 4764-74	12.9	119
72	A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors. <i>Cancer Discovery</i> , <b>2017</b> , 7, 102-113	24.4	105
71	A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 6304-12	12.9	102
70	Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1181-9	2.2	99
69	Preoperative chemoradiation may not always be needed for patients with T3 and T2N+ rectal cancer. <i>Cancer</i> , <b>2011</b> , 117, 3118-25	6.4	76
68	The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target. <i>Cancer Treatment Reviews</i> , <b>2020</b> , 86, 102015	14.4	75
67	Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics. <i>Molecular Cancer Therapeutics</i> , <b>2010</b> , 9, 2844-52	6.1	73
66	The treatment of advanced gastric cancer: current strategies and future perspectives. <i>Annals of Oncology</i> , <b>2008</b> , 19 Suppl 5, v103-7	10.3	67
65	Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer. <i>Cancer Discovery</i> , <b>2015</b> , 5, 598-609	24.4	65
64	Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. <i>Annals of Oncology</i> , <b>2019</b> , 30, 1804-1812	10.3	64
63	Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer. <i>British Journal of Cancer</i> , <b>2017</b> , 117, 1478-1485	8.7	64
62	Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. <i>Annals of Oncology</i> , <b>2010</b> , 21, 1537-1545	10.3	62
61	Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines. <i>Annals of Oncology</i> , <b>2017</b> , 28, iv100-iv118	10.3	49
60	Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial. <i>British Journal of Cancer</i> , <b>2008</b> , 99, 455-8	8.7	48
59	Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens. <i>Breast Cancer Research and Treatment</i> , <b>2010</b> , 120, 245-51	4.4	45

58	Personalized Medicine: Recent Progress in Cancer Therapy. <i>Cancers</i> , <b>2020</b> , 12,	6.6	39
57	Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase. <i>Cancer Research</i> , <b>2011</b> , 71, 675-85	10.1	36
56	Aurora kinase inhibitors: a new class of drugs targeting the regulatory mitotic system. <i>Clinical and Translational Oncology</i> , <b>2009</b> , 11, 787-98	3.6	31
55	Deregulation of ARID1A, CDH1, cMET and PIK3CA and target-related microRNA expression in gastric cancer. <i>Oncotarget</i> , <b>2015</b> , 6, 26935-45	3.3	30
54	NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in -Amplified Gastric Cancer. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 1639-1649	12.9	30
53	The role of chemotherapy in localized and locally advanced rectal cancer: A systematic revision. <i>Cancer Treatment Reviews</i> , <b>2018</b> , 63, 156-171	14.4	26
52	RAS mutations and cetuximab in locally advanced rectal cancer: results of the EXPERT-C trial. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 1430-6	7.5	26
51	Coexistence of EGFR, KRAS, BRAF, and PIK3CA Mutations and ALK Rearrangement in a Comprehensive Cohort of 326 Consecutive Spanish Nonsquamous NSCLC Patients. <i>Clinical Lung Cancer</i> , <b>2017</b> , 18, e395-e402	4.9	25
50	Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer. <i>British Journal of Cancer</i> , <b>2015</b> , 112, 1874-81	8.7	25
49	Selective approach for upper rectal cancer treatment: total mesorectal excision and preoperative chemoradiation are seldom necessary. <i>Diseases of the Colon and Rectum</i> , <b>2015</b> , 58, 556-65	3.1	24
48	How we treat metastatic colorectal cancer. <i>ESMO Open</i> , <b>2020</b> , 4, e000813	6	20
47	Borderline resectable pancreatic cancer. Challenges and controversies. <i>Cancer Treatment Reviews</i> , <b>2018</b> , 68, 124-135	14.4	17
46	Prognostic Impact of pT Stage and Peritoneal Invasion in Locally Advanced Colon Cancer. <i>Diseases of the Colon and Rectum</i> , <b>2019</b> , 62, 684-693	3.1	16
45	Low miR200c expression in tumor budding of invasive front predicts worse survival in patients with localized colon cancer and is related to PD-L1 overexpression. <i>Modern Pathology</i> , <b>2019</b> , 32, 306-313	9.8	16
44	Assessing molecular subtypes of gastric cancer: microsatellite unstable and Epstein-Barr virus subtypes. Methods for detection and clinical and pathological implications. <i>ESMO Open</i> , <b>2019</b> , 4, e000478	6	15
43	Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients. <i>International Journal of Cancer</i> , <b>2020</b> , 146, 94-102	7.5	15
42	Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences. <i>Clinical Cancer Research</i> , <b>2021</b> ,	12.9	14
41	Short- and Long-Term Quality of Life and Bowel Function in Patients With MRI-Defined, High-Risk, Locally Advanced Rectal Cancer Treated With an Intensified Neoadjuvant Strategy in the Randomized Phase 2 EXPERT-C Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2015</b> , 93, 803-12	4	13

40	Parotid gland metastasis of a breast cancer. <i>Clinical and Translational Oncology</i> , <b>2007</b> , 9, 264-5	3.6	13
39	Epigenetic changes in localized gastric cancer: the role of RUNX3 in tumor progression and the immune microenvironment. <i>Oncotarget</i> , <b>2016</b> , 7, 63424-63436	3.3	12
38	Towards precision oncology for HER2 blockade in gastroesophageal adenocarcinoma. <i>Annals of Oncology</i> , <b>2019</b> , 30, 1254-1264	10.3	11
37	Prognostic implications of the standardized study of resection margins in pancreatic cancers. <i>Cirugía Española</i> , <b>2014</b> , 92, 532-8	0.7	11
36	Progress in the multidisciplinary treatment of gastrointestinal cancer and the impact on clinical practice: perioperative management of rectal cancer. <i>Annals of Oncology</i> , <b>2008</b> , 19 Suppl 7, vii266-72	10.3	11
35	Personalised Treatment in Gastric Cancer: Myth or Reality?. <i>Current Oncology Reports</i> , <b>2016</b> , 18, 41	6.3	11
34	Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study. <i>Cancers</i> , <b>2020</b> , 12,	6.6	10
33	Integrating Downstaging in the Risk Assessment of Patients With Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy: Validation of Valentini's Nomograms and the Neoadjuvant Rectal Score. <i>Clinical Colorectal Cancer</i> , <b>2018</b> , 17, 104-112.e2	3.8	10
32	The role of the pathologist in rectal cancer diagnosis and staging and surgical quality assessment. <i>Clinical and Translational Oncology</i> , <b>2010</b> , 12, 339-45	3.6	10
31	Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer. <i>Cancers</i> , <b>2020</b> , 12,	6.6	9
30	Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology. <i>Oncotarget</i> , <b>2016</b> , 7, 22543-55	3.3	9
29	EGF-Induced Acetylation of Heterogeneous Nuclear Ribonucleoproteins Is Dependent on KRAS Mutational Status in Colorectal Cancer Cells. <i>PLoS ONE</i> , <b>2015</b> , 10, e0130543	3.7	8
28	Implementation and assessment of a fast-track programme to improve communication between primary and specialized care in patients with suspected cancer: how to shorten time between initial symptoms of cancer, diagnosis and initiation of treatment. <i>Clinical and Translational Oncology</i> , <b>2015</b> , 17, 167-72	3.6	7
27	FcRIIIa and FcRIIIb polymorphisms and cetuximab benefit in the microscopic disease. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 4511-9	12.9	7
26	Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	7
25	Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review. <i>Cancers</i> , <b>2021</b> , 13,	6.6	7
24	Clinical pharmacokinetics and pharmacodynamics of ramucirumab in the treatment of colorectal cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2016</b> , 12, 449-56	5.5	6
23	Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer. <i>ESMO Open</i> , <b>2020</b> , 5, e000847	6	6

22	Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial). <i>Cancer Chemotherapy and Pharmacology</i> , <b>2018</b> , 82, 935-943	3.5	6
21	SEOM Clinical Guideline of localized rectal cancer (2016). <i>Clinical and Translational Oncology</i> , <b>2016</b> , 18, 1163-1171	3.6	5
20	Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study. <i>Clinical Colorectal Cancer</i> , <b>2021</b> ,	3.8	4
19	Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study. <i>British Journal of Cancer</i> , <b>2021</b> , 125, 1261-1269	8.7	4
18	Improving tumour budding evaluation in colon cancer by extending the assessment area in colectomy specimens. <i>Histopathology</i> , <b>2019</b> , 75, 517-525	7.3	3
17	Circulating tumor DNA to detect minimal residual disease, response to adjuvant therapy, and identify patients at high risk of recurrence in patients with stage I-III CRC.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4009-4009	2.2	3
16	Post-Induction Management in Patients With Left-Sided and Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 712053	5.3	3
15	279 POSTER MLN8054, a selective inhibitor of Aurora A kinase: final results of a phase I clinical trial. <i>European Journal of Cancer, Supplement</i> , <b>2008</b> , 6, 90	1.6	2
14	285 POSTER MLN8237, an oral selective Aurora A kinase inhibitor: initial results of dose-finding pharmacokinetic-pharmacodynamic phase I study. <i>European Journal of Cancer, Supplement</i> , <b>2008</b> , 6, 92	1.6	2
13	Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: oncological outcomes at a single academic centre. <i>ESMO Open</i> , <b>2020</b> , 5, e000929	6	2
12	Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data. <i>Clinical Colorectal Cancer</i> , <b>2021</b> , 20, 227-235	3.8	2
11	Extending neoadjuvant chemotherapy in rectal cancer. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 880-1	21.7	1
10	Impact of perioperative transfusions and sepsis on long-term oncologic outcomes after curative colon cancer resection. A retrospective analysis of a prospective database. <i>Gastroenterología Y Hepatología</i> , <b>2020</b> , 43, 63-72	0.9	1
9	A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?. <i>Supportive Care in Cancer</i> , <b>2021</b> , 30, 2455	3.9	1
8	Impact of perioperative transfusions and sepsis on long-term oncologic outcomes after curative colon cancer resection. A retrospective analysis of a prospective database. <i>Gastroenterología Y Hepatología (English Edition)</i> , <b>2020</b> , 43, 63-72	0.1	
7	Prognostic Implications of the Standardized Study of Resection Margins in Pancreatic Cancers. <i>Cirugía Española (English Edition)</i> , <b>2014</b> , 92, 532-538	0.1	
6	Pancreatic and periampullary tumours: morbidity, mortality, functional results, and long-term survival. <i>Cirugía Española (English Edition)</i> , <b>2009</b> , 86, 159-166	0.1	
5	The actual management of colorectal liver metastases. <i>Minerva Chirurgica</i> , <b>2020</b> , 75, 328-344	0.8	

- 4 Phase 1 study of biweekly (Q2W) anti-EGFR monoclonal antibody (mAb) mixture Sym004 in patients (pts) with metastatic colorectal cancer (mCRC) resistant to previous anti-EGFR treatment.. *Journal of Clinical Oncology*, **2014**, 32, 3551-3551 2.2
- 3 FCR11a and FCR11a polymorphisms (SNPs) and cetuximab (C) benefit in the EXPERT-C trial.. *Journal of Clinical Oncology*, **2014**, 32, 3573-3573 2.2
- 2 Correlation between classical prognostic factors and overexpression of HER2 and HER3 in localized gastric cancer.. *Journal of Clinical Oncology*, **2012**, 30, e14589-e14589 2.2
- 1 Impact of the delivery of adjuvant anthracycline-based nontaxane chemotherapy schedules on the outcome of breast cancer patients: Results from a retrospective database analysis.. *Journal of Clinical Oncology*, **2012**, 30, 1074-1074 2.2